ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article
Revised

Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome

[version 4; peer review: 2 approved]
PUBLISHED 15 Oct 2021
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, categorized into various subtypes. Post-infection IBS may be attributed to the release of cytolethal distending toxin B (CdtB), which cross-reacts with the adhesion protein vinculin responsible for normal intestinal contractility.
Objective: This study aims to identify anti-CdtB and anti-vinculin levels in IBS patients compared to healthy control.
Subjects and methods: This retrospective case-control study was conducted on 100 subjects with IBS, as determined by a questionnaire based on Rome III criteria, recruited from the outpatient clinics of the Tropical Medicine at Mansoura University Hospital from January 2019 to January 2020.
Results: The optical density (OD) results of the anti-vinculin and anti-CdtB levels were significantly elevated in patients with IBS (1.58±0.496 OD, 2.47±0.60 OD)  when compared to control subjects (1.13±0.249 OD, 2.1±0.24 OD), respectively with P=0.001 for both.  Anti-vinculin level was significantly higher in the IBS-D subtype than the other subtypes (P=0.001) while, Anti-CdtB was significantly elevated in IBS-C, IBS-D subgroups compared to control subjects (P=0.001).
Conclusion: Findings of the present study support the hypothesis that IBS results from post-infectious disorders initiated by bacterial enteritis. A hypothesis could be applied to all IBS subgroups. On the other hand. These biomarkers might reflect the post-infectious state's severity.

Keywords

irritable bowel syndrome, anti-vinculin, anti-CdtB, Rome IV

Revised Amendments from Version 3

The OD was added to all sections of the study as it was the correct used unit

See the authors' detailed response to the review by Simon Keely
See the authors' detailed response to the review by Gabriela Leite

Introduction

Irritable bowel syndrome (IBS) is a common gut disorder that affects approximately 11% of the global population.1,2 IBS mainly manifests in subjects with abdominal pain with bowel habit changes in the absence of either radiological evidence of associated pathological conditions or detectable chemical and physiological abnormalities. The diagnosis of this clinical condition relies upon Rome criteria.37

The Rome working team recommended classifying subjects with IBS into different sub-groups depending on their bowel habits changes predominance. The IBS sub-groups included IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), Mixed IBS (IBS-M), and Un-subtyped IBS.3

To understand the pathogenesis of irritable bowel syndrome (IBS), previous studies have developed a rat model utilizing infection with Campylobacter jejuni in order to elicit a post-infection phenotype resembling human post-infection IBS (PI-IBS) characterized by apparent changes in the composition of small intestinal microbiota.8,9 In these studies, progression to IBS was accompanied by the detection of a specific bacterial toxin named cytolethal distending toxin B (CdtB), a potential factor attributing to the pathogenesis of PI-IBS. Experimental studies suggested a low incidence of IBS when infected with a mutant strain of C. jejuni that lacks CdtB.8,10

Furthermore, the development of antibodies to CdtB was associated with altering gut microbiota associated with reducing specific interstitial cells of Cajal (ICC).11,12 These findings were linked to the ability of anti-CdtB to cross-react with vinculin, a host cell adhesion protein present in interstitial cells of Cajal and the myenteric ganglia that control the normal activity of the intestinal tract, including phase III of inter-digestive motor activity.13 Absence or decrease in phase III contractions results in small intestinal bacterial overgrowth in animal models and human patients with IBS.14,15 In this sense, autoimmunity may profoundly affect the host immune response to infections with C. jejuni, subsequently leading to IBS.16,17 Based on these data, it has been suggested that loss of vinculin in the neuromuscular system of the gastrointestinal tract (GIT) may be associated with the affection of the gut in animal models of post-infection C. jejuni. Detection of circulating levels of anti-CdtB and anti-vinculin by enzyme-linked immunosorbent assay (ELISA) has been used to identify patients with IBS-D,18 and to differentiate it from other IBS subtypes.19 However, it should be noted that the idea of a specific IBS microbiome is someone controversial with larger studies analysing mucosal microbiomes showing now distinct signature.20

The present study aims to detect and quantify anti-CdtB and anti-vinculin levels in subjects with IBS and their possible role in diagnosing different IBS subtypes.

Methods

This was a retrospective case-control study comprising 100 adult patients aged >18 years with IBS, recruited from the Tropical Medicine Department's outpatient clinics at Mansoura University Hospital from January 2019 to January 2020, and 100 healthy subjects with matched gender and age as a control group.

Selection and exclusion criteria

Patients were recruited and IBS determined by a questionnaire-based upon the Rome III criteria, then classified according to their predominant stool composition over 25% of the time: into IBS-C (hard or lumpy stools), IBS-D (loose and watery stools), or IBS-M (a mix of both types).19 Exclusion criteria included patients with hepatic, renal, or autoimmune diseases, those with history of inflammatory bowel disease, gastrointestinal surgeries, thyroid disorders, diabetes mellitus, and patients with a history of taking antibiotics in the last 30 days.

Laboratory methods

A 10 ml blood sample was obtained from each subject, which was then divided into three aliquots. Two aliquots were used to determine complete blood counts, and one aliquot was utilized for serum separation to assess complete liver function tests, including alanine transaminase, aspartate transaminase, total bilirubin, total albumin, and the kidney function test creatinine. The third aliquot was overlaid on heparin for plasma separation, and the remaining sera were stored at -20°C to be used for evaluation of anti-vinculin antibodies by laboratory prepared ELISA and anti-CdtB antibodies by commercial ELISA (Creative Diagnostics. 45-16 Ramsey Road Shirley, NY 11967, USA).

ELISA for anti-vinculin

Anti-vinculin levels were measured in separated plasma using human vinculin protein in a concentration of 1.2 μg/ml (Novoprotein Scientific, Summit, New Jersey, USA) as an antigen. The vinculin was used to coat wells of the plate following overnight incubation in the wells at 4°C with 100 mmol/l borate buffered saline AQ4 at a pH of 8.2 (Sigma-Aldrich). The reaction was blocked by using BSA 3% and incubating for one hour at room temperature, then washing three times with 0.05% PBS and Tween 20 (pH 7.4). Plasma was added after a 1:32 dilution in saline, then antibodies for vinculin (R and D Systems Cat# MAB6896, RRID:AB_10992930), were added as positive control and incubated for one hour at room temperature followed by washing three times with 0.05% PBS and Tween 20 (pH 7.4). Horseradish peroxidase-conjugated secondary antibodies (Millipore–Merck) were added and incubated for one hour at room temperature. After washing, a tetramethylbenzidine substrate solution (BioRad) was used for detection using a micro-plate reader (stat Fax-1200; Awareness Technology, Florida, USA). Optical densities (ODs) were read at 370nm, and the results were interpreted as OD.12

ELISA for anti-CdtB (creative diagnostics)

The ELISA was used to determine the anti-CdTB of C. jejuni using the recombinant Campylobacter CdtB protein (https://www.creativebiomart.net/description_436265_12.htm). The protein was used as antigens immobilized at the wells of the 96 microplates overnight at 4 C with a concentration of 1.2 μg/mL prepared in borate buffer saline to obtain PH 8.2. Negative wells were prepared by adding only borate buffer saline. After overnight incubation, the reaction was blocked by adding bovine albumin with a concentration of 3% prepared in phosphate buffer and incubated at room temperature for one hour. Then the plate was used to determine anti-CdtB in the serum samples with dilution 1:512, and anti-CdtB antibodies) were used as positive controls (https://www.creative-diagnostics.com/search.aspx?pageid=1&keys=CdtB&status=0&fl=ELISA%257e&flt=2,&cid=4). The plate was incubated for one hour at room temperature. The wells were then washed three times with phosphate buffer, and then horseradish peroxidase-conjugated secondary antibodies were added to the wells and incubated for one hour at room temperature. TMB turns blue in peroxidase reaction and finally turns yellow under the action of acid. Optical densities (ODs) were read at 450. The OD values were used for the data analysis.

Statistical analysis

Data are reported as means and standard deviation (SD) or counts and percentages when appropriate. Comparisons between groups were made using t-tests, Mann-Whitney tests, Chi-square, or Fisher exact tests dictated by data type and distribution.

One-way analysis of variance (ANOVA) was used to test differences between more than two groups. P-value < 0.05 was considered significant for all statistical analyses in this study. All analyses were performed using the Statistical Package of Social Sciences (SPSS) version 22 for Windows (SPSS, Inc., Chicago, IL, USA).

Results

This study included 100 patients with IBS (49 males and 51 females) aged 46.6 ± 6.8 years and 100 healthy controls with a statistically insignificant difference between patients and control regarding age and sex (P = 0.8 and P = 0.6, respectively). Patients were classified according to Rome III criteria into 40 patients with IBS-C, 26 patients with IBS-D, and 34 patients with IBS-M (Figure 1). Laboratory investigations, including ALT, AST, albumin, total bilirubin, hemoglobin, total leucocytes count, platelets, and creatinine, showed non-significant differences between patients and control subjects (P = 0.6, P = 0.5, P = 0.7, P = 0.6, P = 0.99, P = 0.99, and P = 0.58) respectively (Table 1).

5e0f080e-d08d-4bf1-91fc-4e8f6bef987b_figure1.gif

Figure 1. Distribution of patients according to Rome III criteria.

Table 1. Comparison of demographic and laboratory findings between patients and control subjects.

ParameterPatients with IBS
(n = 100)
Healthy Control
(n = 100)
P
Age (Mean ± SD)50.1 ± 6.646.6 ± 6.80.8
Sex

  • Male (No/%)

  • Female (No/%)

49 (49%)
51 (51%)
49 (49%)
51 (51%)
0.6
Hemoglobin
(Mean ± SD) gm/dl
13.19 ± 1.713.16 ± 1.70.99
Total leucocytes count
(Mean ± SD) × 103/mm3
13.2 ± 1.713.1 ± 1.80.99
Platelets
(Mean ± SD) × 103/mm3
134.15 ± 56.32141.35 ± 34.040.003
Creatinine
(Mean ± SD) mg/dl
0.98 ± 0.250.96 ± 0.280.58
ALT (Mean ± SD) IU/l28.85 ± 4.729.2 ± 4.40.6
AST (Mean ± SD)27.26 ± 4.3227.7 ± 4.050.5
Albumin
(Mean ± SD) gm/dl
4.00 ± 0.514.1 ± 0.520.7
Total bilirubin
(Mean ± SD) mg/dl
0.82 ± 0.100.9 ± 0.110.6

The OD of the anti-vinculin and anti-CdtB levels were significantly elevated in IBS patients (1.58 ± 0.496ng/ml and 2.47 ± 0.60 ng/ml) respectively compared to the control subjects (1.13 ± 0.249 ng/ml and 2.1 ± 0.24 ng/ml) respectively with P = 0.001 for both (Table 2).

Table 2. Comparison of anti-vinculin and anti-CdtB in patients with IBS versus control subjects.

ParameterPatients with IBS
(Mean ± SD)
Control Subjects
(Mean ± SD)
P
Anti-vinculin1.58 ± 0.4961.13 ± 0.2490.001
Anti-CdtB2.47 ± 0.602.1 ± 0.240.001

Anti-vinculin levels were also significantly higher in different IBS subgroups compared to control subjects, with the anti-vinculin level being significantly elevated in the IBS-D subtype when compared to the other subtypes with P = 0.001. Similarly, anti-CdtB showed significant elevation in IBS-C and IBS-D compared to control subjects (P = 0.001), with a significantly higher level detected in IBS-D than IBS-C (P = 0.001). However, the level of anti-CdtB in IBS-M was detected at a non-significant lower level compared to control subjects (P = 0.2), but at a significantly lower level when compared to IBS-C and IBS-D (P = 0.001) (Table 3).

Table 3. Comparison of anti-vinculin and anti-CdtB between different subgroups of IBS and control subjects.

ParameterIBS-C
(N = 40)
(OD mean ± SD)
IBS-D
(N = 26)
(OD mean ± SD)
IBS-M
(N = 34)
(OD mean ± SD)
Control
(N = 100)
(OD mean ± SD)
P
Anti-vinculin1.33 ± 0.491.84 ± 0.421.68 ± 0.421.13 ± 0.25P1 = 0.001
P2 = 0.001
P3 = 0.001
P4 = 0.01
P5 = 0.001
P6 = 0.001
Anti-CdtB2.52 ± 0.462.98 ± 0.62.03 ± 0.672.1 ± 0.24P = 0.001
P1 = 0.001
P2 = 0.001
P3 = 0.001
P4 = 0.2
P5 = 0.001
P6 = 0.001

Discussion

There is an extreme necessity for the utilization of accessible and reliable, low-cost biomarkers to avoid unnecessary routine use of colonoscopy in diagnosing IBS in low-risk population with age <50 years, no history of GIT bleeding, nocturnal passage of stool, weight loss, familial history of inflammatory bowel diseases or colorectal cancer, recent bowel habits changes, and/or the presence of abdominal masses or lymaphadenopathy.1,20 Previous studies reported that anti-CdtB and anti-vinculin might be valuable noninvasive biomarkers to identify IBS patients21,22 in different populations. However, these biomarkers have not been sufficiently evaluated in Egyptian patients.

In the current study, both anti-vinculin and anti-CdtB demonstrated significantly elevated levels in IBS patients when compared to the control subjects, a finding that mirrors those from a previous study by Talley et al.23 However, data reported by Rezaie et al.16 depicts significant elevation in levels of both biomarkers only in IBS-M and IBS-D, but not IBS-C. This discrepancy in findings may be attributed to the difference in etiology of different IBS subtypes,4 as it is hypothesized that most cases of post-infectious IBS manifest as IBS-D or IBS-M, with a minority of patients manifesting as IBS-C.9 Another factor may make the microbiome profile difference between IBS patient subgroups; bacterial species producing methane are decreased in IBS-D and IBS-M23 and increased in IBS-C.24 Patients included in the present study, particularly those in the IBS-C subgroup, may represent patients who develop IBS following infections associated with their microbiota profile changes. These findings need extensive longitudinal studies to be confirmed.

Anti-vinculin and anti-CdtB levels in this study were significantly elevated in patients with IBS-D, a concordance finding with Pimentel et al., who reported that anti-CdtB and anti-vinculin distinguished IBS-D from IBD, other organic GI diseases and healthy control. In addition, Bayoumy et al.24 reported that anti-vinculin could be an important biomarker for IBS-D diagnosis among Egyptian patients. Cytolethal distending toxin represents a virulence factor for bacterial pathogens such as Escherichia coli, Salmonella, Shigella, and Campylobacter jejuni, by causing epithelial barrier breakdown and suppression of the acquired immune response to invading pathogens, resulting in an amplified pro-inflammatory response with consequent persistence of bacterial infection.16 Development of anti-CdtB antibodies occurs in response to secretion of cytolethal distending toxin following infection with bacterial pathogens. Molecular mimicry accounts for the potential cross-reaction between anti-CdtB and vinculin with resultant anti-vinculin autoantibody production leading to injury to interstitial cells of Cajal (ICC) with the development of IBS.12 Based on the suggestion of an association between the metabolic syndrome and liver affection and IBS, this study group performed liver function tests as a simple evaluation of liver affection. However, liver enzymes were normal in IBS patients' studied group, in contrast to reports by Lee et al.26

In the present study there was no history of previous infection with C. jejuni. However, the elevated levels of antiCdtB and antivinculin can be used as biomarkers for diagnosis of IBS either post infections or without previous infection. The data of the present study supports that PI IBS may be more common than it is realized.26

The principal limitation of the present study was the lack of psychological measures in combination with the measurement of the serological biomarkers as these measures are a valuable tool in the diagnosis of IBS compared to healthy controls as reported previously.27

Conclusion

The present findings support the hypothesis that IBS may results from post-infectious bacterial gastroenteritis. Moreover, this hypothesis can be applied to all IBS subgroups as both anti-CdtB and anti-vinculin biomarkers were significantly elevated in IBS-C and IBS-D subgroups, with only anti-vinculin being elevated in IBS-M when compared to healthy control. These may signify the role of infection in such subgroup of IBS patients. These findings need further extensive longitudinal studies in patients with IBS.

Consent

All participants provided written informed consent and the study was conducted according to the principles outlined in the Declaration of Helsinki. Confidentiality and privacy were considered regarding personal, clinical and laboratory data.

Ethical approval

Mansoura Faculty of Medicine Institutional Research Board approved the research (R.21.01.1141).

Data availability

Figshare: “Study of antibodies to cytolethal distending toxin B (CdtB) and antibodies to vinculin in patients with irritable bowel syndrome” https://doi.org/10.6084/m9.figshare.14178908.v1.28

Data are available under the terms of the Creative Commons CC BY 4.0

Comments on this article Comments (0)

Version 4
VERSION 4 PUBLISHED 19 Apr 2021
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Zaki MES, Elhammady D, Foda Salama M et al. Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.12688/f1000research.52086.4)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 4
VERSION 4
PUBLISHED 15 Oct 2021
Revised
Views
2
Cite
Reviewer Report 25 Oct 2021
Gabriela Leite, Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Approved
VIEWS 2
Minor change:
  • Authors did not correct the cdtB and vinculin units in the results section as requested previously. - "The OD of the anti-vinculin and anti-CdtB levels were significantly elevated in IBS patients (1.58 ± 0.496ng/ml
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Leite G. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.77874.r97035)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 3
VERSION 3
PUBLISHED 23 Aug 2021
Revised
Views
6
Cite
Reviewer Report 29 Sep 2021
Simon Keely, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia 
Approved
VIEWS 6
I have ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Keely S. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.58688.r94996)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 08 Oct 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    08 Oct 2021
    Author Response
    Thanks Sir for your great efforts
    Competing Interests: No competing interests were disclosed.
COMMENTS ON THIS REPORT
  • Author Response 08 Oct 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    08 Oct 2021
    Author Response
    Thanks Sir for your great efforts
    Competing Interests: No competing interests were disclosed.
Views
11
Cite
Reviewer Report 31 Aug 2021
Gabriela Leite, Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Approved with Reservations
VIEWS 11
The authors did not correct the units for antibodies anti-vinculin and anti-cdtB as suggested previously. Neither Results or Abstract were corrected on version 3 of the manuscript. The authors need to clarify the choice of reporting the values as ng/mL, ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Leite G. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.58688.r92547)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 02 Sep 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    02 Sep 2021
    Author Response
    The results of units for antibodies anti-vinculin and anti-cdtB was expressed as OD values as mentioned in the method section. I will add the OD to the abstract and in ... Continue reading
  • Author Response 27 Sep 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    27 Sep 2021
    Author Response
    The OD was added to all sections of the study as it was the correct used unit.
    Competing Interests: No competing interests were disclosed.
COMMENTS ON THIS REPORT
  • Author Response 02 Sep 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    02 Sep 2021
    Author Response
    The results of units for antibodies anti-vinculin and anti-cdtB was expressed as OD values as mentioned in the method section. I will add the OD to the abstract and in ... Continue reading
  • Author Response 27 Sep 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    27 Sep 2021
    Author Response
    The OD was added to all sections of the study as it was the correct used unit.
    Competing Interests: No competing interests were disclosed.
Version 2
VERSION 2
PUBLISHED 30 Jun 2021
Revised
Views
13
Cite
Reviewer Report 09 Jul 2021
Gabriela Leite, Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Approved with Reservations
VIEWS 13
The authors addressed and clarified all comments. Thank you for that. One last adjustment:

On the paragraph below from Results, the units for cdtB and vinculin antibodies levels should be double checked. The levels were measured considering ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Leite G. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.57371.r88732)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 13 Jul 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    13 Jul 2021
    Author Response
    Thanks for your accurate review, I will respond
    Competing Interests: No competing interests were disclosed.
  • Author Response 23 Aug 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    23 Aug 2021
    Author Response
    • On the paragraph below from Results, the units for cdtB and vinculin antibodies levels should be double checked. The levels were measured considering the OD results. If authors
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 13 Jul 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    13 Jul 2021
    Author Response
    Thanks for your accurate review, I will respond
    Competing Interests: No competing interests were disclosed.
  • Author Response 23 Aug 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    23 Aug 2021
    Author Response
    • On the paragraph below from Results, the units for cdtB and vinculin antibodies levels should be double checked. The levels were measured considering the OD results. If authors
    ... Continue reading
Views
14
Cite
Reviewer Report 07 Jul 2021
Simon Keely, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia 
Approved with Reservations
VIEWS 14
It is very disappointing to see the author's responses to my comments. The comments have largely been dismissed, ignored or superficially addressed and there are errors and discrepancies in the article that have not been amended.

Referring ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Keely S. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.57371.r88731)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 08 Jul 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    08 Jul 2021
    Author Response
    The response will be performed in more detail.
    Competing Interests: No competing interests were disclosed.
  • Author Response 23 Aug 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    23 Aug 2021
    Author Response
    • The authors amended text "the following was added: 'In the present study there was no history of previous infection with C. jejuni. However, the elevated levels of antiCdtB and
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 08 Jul 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    08 Jul 2021
    Author Response
    The response will be performed in more detail.
    Competing Interests: No competing interests were disclosed.
  • Author Response 23 Aug 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    23 Aug 2021
    Author Response
    • The authors amended text "the following was added: 'In the present study there was no history of previous infection with C. jejuni. However, the elevated levels of antiCdtB and
    ... Continue reading
Version 1
VERSION 1
PUBLISHED 19 Apr 2021
Views
14
Cite
Reviewer Report 11 Jun 2021
Simon Keely, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia 
Approved with Reservations
VIEWS 14
This is an interesting study validating previous work on the utility of CdtB and vinculin as potential biomarkers for functional GI disorders, specifically IBS.

The study is clearly reported although there are a number of inconsistencies that ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Keely S. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.55313.r85381)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 14 Jun 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    14 Jun 2021
    Author Response
    Thanks for reviewing the article. The response will be followed.
    Competing Interests: There is no any competing interest
  • Author Response 30 Jun 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    30 Jun 2021
    Author Response
    Response to reviewers: 

    We would like to thank the reviewer the insightful comments on the paper, as these comments led us to an improvement of the work. Our revisions ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 14 Jun 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    14 Jun 2021
    Author Response
    Thanks for reviewing the article. The response will be followed.
    Competing Interests: There is no any competing interest
  • Author Response 30 Jun 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    30 Jun 2021
    Author Response
    Response to reviewers: 

    We would like to thank the reviewer the insightful comments on the paper, as these comments led us to an improvement of the work. Our revisions ... Continue reading
Views
46
Cite
Reviewer Report 27 May 2021
Gabriela Leite, Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA 
Approved with Reservations
VIEWS 46
In this study, Zaki and collaborators observed increased levels of plasma CdtB and vinculin antibodies in IBS subjects when compared to controls (non-IBS subjects) and analysis also revealed differences between IBS subtypes. The study has an important clinical relevance, but ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Leite G. Reviewer Report For: Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome [version 4; peer review: 2 approved]. F1000Research 2021, 10:303 (https://doi.org/10.5256/f1000research.55313.r86122)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 30 Jun 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    30 Jun 2021
    Author Response
    Response to reviewers:

    We would like to thank the reviewer the insightful comments on the paper, as these comments led us to an improvement of the work. Our revisions ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 30 Jun 2021
    Maysaa El Zaki, Clinical Pathology, Mansoura University, Mansoura, Egypt
    30 Jun 2021
    Author Response
    Response to reviewers:

    We would like to thank the reviewer the insightful comments on the paper, as these comments led us to an improvement of the work. Our revisions ... Continue reading

Comments on this article Comments (0)

Version 4
VERSION 4 PUBLISHED 19 Apr 2021
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.